Unlocking the Potential of CYLD-AS1: A drug Target or Biomarker?

Target Name: CYLD-AS1

NCBI ID: G102724907

CYLD-AS1

Other Name(s): LOC102724907 variant X6 | LOC102724907 variant X5 | CYLD antisense RNA 1 | Uncharacterized LOC102724907, transcript variant X5 | Uncharacterized LOC102724907, transcript variant X6

Unlocking the Potential of CYLD-AS1: A drug Target or Biomarker?

Cysteinyl-cysteine protein (CYLD) is a 21-kDa protein that is expressed in various tissues, including brain, heart, lungs, and liver. Cysteinyl-cysteine protein is involved in various cellular processes, including cell signaling, inflammation, and stress response. One of the variants of CYLD, CYLD-AS1, has been identified and is of interest as a potential drug target or biomarker.

CYLD-AS1 Variants

Cysteinyl-cysteine protein (CYLD) has four variants: CYLD-AS1, CYLD-AS2, CYLD-AS3, and CYLD-AS4. CYLD-AS1 is a rare variant that is expressed in only a few tissues, including brain, heart, and spleen. CYLD-AS2 and CYLD-AS3 are more common variants that are expressed in various tissues throughout the body, including muscle, liver, kidney, and pancreas. CYLD-AS4 is a rare variant that is expressed in only a few tissues, including heart and spleen.

CYLD-AS1 Functions

CYLD-AS1 is involved in various cellular processes, including cell signaling, inflammation, and stress response. It is a protein that is involved in the regulation of protein-protein interactions, including the interaction between the protein and the cytosol. It is also involved in the regulation of DNA replication and transcription.

CYLD-AS1 as a Drug Target

CYLD-AS1 is a potential drug target due to its involvement in various cellular processes. One of the potential strategies to target CYLD-AS1 is to inhibit its activity by blocking the interaction between CYLD-AS1 and other proteins. This can be done by using small molecules, antibodies, or other therapeutic agents that can interact with CYLD-AS1 and prevent its activity.

CYLD-AS1 as a Biomarker

CYLD-AS1 may also be used as a biomarker for various diseases. One of the potential applications of CYLD-AS1 is as a diagnostic biomarker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The levels of CYLD-AS1 in the brain can be used to diagnose these diseases and to monitor the effectiveness of various treatments.

CYLD-AS1 Interactions

CYLD-AS1 interacts with various proteins, including microtubules, actin, and transcription factors. It is also involved in the regulation of protein-protein interactions, including the interaction between CYLD-AS1 and the cytosol. These interactions may have implications for the functions of CYLD-AS1 and its role in various cellular processes.

Conclusion

Cysteinyl-cysteine protein (CYLD) is a 21-kDa protein that is involved in various cellular processes, including cell signaling, inflammation, and stress response. One of the variants of CYLD, CYLD-AS1, has been identified and may be a potential drug target or biomarker. The levels of CYLD-AS1 in various tissues can be used to diagnose neurodegenerative diseases and to monitor the effectiveness of various treatments. Further research is needed to fully understand the functions of CYLD-AS1 and its potential as a drug target or biomarker.

Protein Name: CYLD Antisense RNA 1

The "CYLD-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYLD-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets